EvaluatioN of HIFU Hemiablation and Short Term AndrogeN Deprivation Therapy Combination to Enhance Prostate Cancer Control. (ENHANCE)
EvaluatioN of High-intensity Focused Ultrasound (HIFU) Hemiablation and Short Term AndrogeN Deprivation Therapy Combination to Enhance Prostate Cancer Control for Intermediate Risk Localized Prostate Cancer: the ENHANCE Prospective Feasibility Trial.
Sponsor: Institut Mutualiste Montsouris
This PHASE2 trial investigates Androgen Deprivation Therapy and Prostate Cancer and is currently ongoing. Institut Mutualiste Montsouris leads this study, which shows 8 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Feb 2025 — Present [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Jan 2022 — Feb 2023 [monthly]
Unknown Status PHASE2
Status: Not Yet Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jan 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2019 — Oct 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Institut Mutualiste Montsouris
- University of Turin, Italy
For direct contact, visit the study record on ClinicalTrials.gov .